Clinical Trial

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-07-10.
Trial Details
NCT Number NCT05951816
Lead Sponsor University of Tennessee Graduate School of Medicine
Collaborators: Bayer
Conditions Systemic Amyloidosis
Enrollment 31 participants
Start Date 2023-09-18
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-24